

---

***BIBLIOGRAFIA***



**BIBLIOGRAFIA**

AGRAWAL, Y.K. [*et al.*] – Chirality: A New Era of Therapeutics. **Mini Rev. Med. Chem.** 7:5 (2007) 451-460.

ALI, I. [*et al.*] – Role of Racemization in Optically Active Drugs Development. **Chirality.** 19:6 (2007) 453-463.

ALMEIDA, A.M.; CASTEL-BRANCO, M.M.; FALCÃO, A.C. – Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. **J. Chromatogr. B.** 774:2 (2002) 215-222.

ALMEIDA, L. [*et al.*] – Single-Dose and Steady-State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093) in Healthy Elderly and Young Subjects. **J. Clin. Pharmacol.** 45:9 (2005) 1062-1066.

ALMEIDA, L. [*et al.*] – Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. **Eur. J. Clin. Pharmacol.** 64:3 (2008) 267-273.

ALMEIDA, L.; SOARES-DA-SILVA, P. – Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans. **Drugs R&D.** 4:5 (2003) 269-284.

ALMEIDA, L.; SOARES-DA-SILVA, P. – Safety, Tolerability, and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic, in a Rising Multiple-Dose Study in Young Healthy Humans. **J. Clin. Pharmacol.** 44:8 (2004) 906-918.

ALMEIDA, L.; SOARES-DA-SILVA, P. – Eslicarbazepine Acetate (BIA 2-093). **Neurotherapeutics.** 4:1 (2007) 88-96.

ALVES, G. [*et al.*] – Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. **Biomed. Chromatogr.** 21:11 (2007a) 1127-1134.

ALVES, G. [*et al.*] – Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. **Anal. Chim. Acta.** 596:1 (2007b) 132-140.

ALVES, G. [*et al.*] – Disposition of Eslicarbazepine Acetate in the Mouse after Oral Administration. **Fundam. Clin. Pharmacol.** (2008a) (Aceite para publicação).

ALVES, G. [*et al.*] – Stereoselective Disposition of S- and R-Licarbazepine in Mice. **Chirality.** 20:6 (2008b) 796-804.

AMBRÓSIO, A.F. [*et al.*] – Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. **Biochem. Pharmacol.** 61:10 (2001) 1271-1275.

- AMBRÓSIO, A.F. [*et al.*] – Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024. **Neurochem. Res.** 27:1-2 (2002) 121-130.
- AMBRÓSIO, A.F. [*et al.*] – Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. **Eur. J. Pharmacol.** 406:2 (2000) 191-201.
- AMORE, B.M. [*et al.*] – Characterization of Carbamazepine Metabolism in a Mouse Model of Carbamazepine Teratogenicity. **Drug Metab. Dispos.** 25:8 (1997) 953-962.
- ANDERSSON, T. – Single-Isomer Drugs: True Therapeutic Advances. **Clin. Pharmacokinet.** 43:5 (2004) 279-285.
- ARAÚJO, I.M. [*et al.*] – Neurotoxicity Induced by Antiepileptic Drugs in Cultured Hippocampal Neurons: A Comparative Study between Carbamazepine, Oxcarbazepine, and Two New Putative Antiepileptic Drugs, BIA 2-024 and BIA 2-093. **Epilepsia.** 45:12 (2004) 1498-1505.
- ARMJO, J.A. [*et al.*] – Ion Channels and Epilepsy. **Curr. Pharm. Des.** 11:15 (2005) 1975-2003.
- ARROYO, S.; KRAMER, G. – Treating Epilepsy in the Elderly: Safety Considerations. **Drug Saf.** 24:13 (2001) 991-1015.
- BANG, L.M.; GOA, K.L. – Oxcarbazepine: A Review of its Use in Children with Epilepsy. **Paediatr. Drugs.** 5:8 (2003) 557-573.
- BANG, L.M.; GOA, K.L. – Spotlight on Oxcarbazepine in Epilepsy. **CNS Drugs.** 18:1 (2004) 57-61.
- BAR-OZ, B. [*et al.*] – Anticonvulsants and Breast Feeding: A Critical Review. **Paediatr. Drugs.** 2:2 (2000) 113-126.
- BATTINO, D.; ESTIENNE, M.; AVANZINI, G. – Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients. Part II. Phenytoin, Carbamazepine, Sulthiame, Lamotrigine, Vigabatrin, Oxcarbazepine and Felbamate. **Clin Pharmacokinet.** 29:5 (1995) 341-369.
- BAZIL, C.W.; PEDLEY, T.A. – Advances in the medical treatment of epilepsy. **Annu. Rev. Med.** 49 (1998) 135-162.
- BEGHI, E. – Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. **Lancet Neurol.** 3:10 (2004) 618-621.
- BENES, J. [*et al.*] – Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives. **J. Med. Chem.** 42:14 (1999) 2582-2587.
- BEN-MENACHEM, E. – Vagus-nerve stimulation for the treatment of epilepsy. **Lancet Neurol.** 1:8 (2002) 477-482.
- BERG, A.T.; BLACKSTONE, N.W. – Concepts in classification and their relevance to epilepsy. **Epilepsy Res.** 70:Suppl. 1 (2006) S11-S19.

- BERKOVIC, S.F. [et al.] – Human epilepsies: interaction of genetic and acquired factors. **Trends Neurosci.** 29:7 (2006) 391-397.
- BERNUS, I. [et al.] – The mechanism of the carbamazepine-valproate interaction in humans. **Br. J. Clin. Pharmacol.** 44:1 (1997) 21-27.
- BERTILSSON, L. – Clinical Pharmacokinetics of Carbamazepine. **Clin. Pharmacokinet.** 3:2 (1978) 128-143.
- BERTILSSON, L.; TOMSON, T. – Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxy. An Update. **Clin. Pharmacokinet.** 11:3 (1986) 177-198.
- BEYDOUN, A.; KUTLUAY, E. – Oxcarbazepine. **Expert Opin. Pharmacother.** 3:1 (2001) 59-71.
- BIALER, M. – New Antiepileptic Drugs Currently in Clinical Trials: Is There a Strategy in Their Development? **Ther. Drug Monit.** 24:1 (2002) 85-90.
- BIALER, M. – New antiepileptic drugs that are second generation to existing antiepileptic drugs. **Expert Opin. Investig. Drugs.** 15:6 (2006) 637-647.
- BIALER, M. [et al.] – Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference. **Epilepsy Res.** 25:3 (1996) 299-319.
- BIALER, M. [et al.] – Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). **Epilepsy Res.** 34:1 (1999) 1-41.
- BIALER, M. [et al.] – Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). **Epilepsy Res.** 51:1-2 (2002) 31-71.
- BIALER, M. [et al.] – Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). **Epilepsy Res.** 61 (2004) 1-48.
- BIALER, M. [et al.] – Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII). **Epilepsy Res.** 73:1 (2007) 1-52.
- BONIFÁCIO, M.J. [et al.] – Interaction of the Novel Anticonvulsant, BIA 2-093, with Voltage-Gated Sodium Channels: Comparison with Carbamazepine. **Epilepsia.** 42:5 (2001) 600-608.
- BOON, P. [et al.] – Vagus nerve stimulation for refractory epilepsy. **Seizure.** 10:6 (2001) 448-455.
- BOUGH, K.J.; RHO, J.M. – Anticonvulsant Mechanisms of the Ketogenic Diet. **Epilepsia.** 48:1 (2007) 43-58.
- BRESSOLLE, F.; BROMET-PETIT, M.; AUDRAN, M. – Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. **J. Chromatogr. B.** 686:1 (1996) 3-10.

- BRETON, H. [*et al.*] – Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. **J. Chromatogr. B.** 828:1-2 (2005) 80-90.
- BROCKS, D.R. – Drug Disposition in Three Dimensions: An Update on Stereoselectivity in Pharmacokinetics. **Biopharm. Drug Dispos.** 27:8 (2006) 387-406.
- BRODIE, M.J.; FRENCH, J.A. – Management of epilepsy in adolescents and adults. **Lancet.** 356:9226 (2000) 323-329.
- BRODIE, M.J.; KWAN, P. – The Star Systems: Overview and Use in Determining Antiepileptic Drug Choice. **CNS Drugs.** 15:1 (2001) 1-12.
- BROWN, H.S. [*et al.*] – Prediction of *In Vivo* Drug-Drug Interactions from *In Vitro* Data. Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4. **Clin. Pharmacokinet.** 45:10 (2006) 1035-1050.
- BRUNBECH, L.; SABERS, A. – Effect of Antiepileptic Drugs on Cognitive Function in Individuals with epilepsy: A Comparative Review of Newer Versus Older Agents. **Drugs.** 62:4 (2002) 593-604.
- BUGAMELLI, F. [*et al.*] – Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. **Anal. Chim. Acta.** 472:1-2 (2002) 1-10.
- BUICK, A.R. [*et al.*] – Method validation in the bioanalytical laboratory. **J. Pharm. Biomed. Anal.** 8:8-12 (1990) 629-637.
- BÜLAU, P.; PAAR, W.D.; VON UNRUH, G.E. – Pharmacokinetics of Oxcarbazepine and 10-Hydroxy-carbazepine in the Newborn Child of an Oxcarbazepine-Treated Mother. **Eur. J. Clin. Pharmacol.** 34:3 (1988) 311-313.
- CALDWELL, J. – Stereochemical determinants of the nature and consequences of drug metabolism. **J. Chromatogr. A** 694:1 (1995) 39-48.
- CALDWELL, J. – Importance of stereospecific bioanalytical monitoring in drug development. **J. Chromatogr. A** 719:1 (1996) 3-13.
- CASABÓ ALÓS, V.G.; MERINO SANJUÁN, M. – Análisis no compartimental y modelado fisiológico. In DOMÉNECH BERROZPE, J; MARTÍNEZ LANAO, J; PLÁ DELFINA, J.M., ed. lit. – **Biofarmacia y Farmacocinética.** Madrid: Editorial Síntesis, 1997. Vol 1, Cap. 4, p.39-51.
- CASCINO, G.D. – Surgical treatment for epilepsy. **Epilepsy Res.** 60:2-3 (2004) 179-186.
- CASTEL-BRANCO, M.M. [*et al.*] – Lamotrigine kidney distribution in male rats following a single intraperitoneal dose. **Fundam. Clin. Pharmacol.** 18:1 (2004) 51-55.

CAUSEY, A.G.; HILL, H.M.; PHILLIPS, L.J. – Evaluation of criteria for the acceptance of bioanalytical data. **J. Pharm. Biomed. Anal.** 8:8-12 (1990) 625-628.

CEPELAK, I. [*et al.*] – Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children. **Clin. Chim. Acta.** 276:2 (1998) 121-127.

CHANDRAN, S.; SINGH, R.S.P. – Comparison of various international guidelines for analytical method validation. **Pharmazie.** 62:1 (2007) 4-14.

CHENG, X. [*et al.*] – Determination of methacycline in human plasma by liquid chromatography coupled to tandem mass spectrometry. **Anal. Chim. Acta.** 553:1-2 (2005) 15-20.

CHRISTENSEN, J. [*et al.*] – Plasma Concentration of Topiramate Correlates with Cerebrospinal Fluid Concentration. **Ther. Drug Monit.** 23:5 (2001) 529-535.

CLEMENS, B.; MÉNES, A.; NAGY, Z. – Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine. **Acta Neurol. Scand.** 109:5 (2004) 324-329.

CLEMENS, P.L. [*et al.*] – Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. **Clin. Drug. Investig.** 27:4 (2007) 243-250.

CLINCKERS, R. [*et al.*] – Quantitative in Vivo Microdialysis Study on the Influence of Multidrug Transporters on the Blood-Brain Barrier Passage of Oxcarbazepine: Concomitant Use of Hippocampal Monoamines as Pharmacodynamic Markers for the Anticonvulsant Activity. **J. Pharmacol. Exp. Ther.** 314:2 (2005) 725-731.

COMMISSION on Classification and Terminology of the International League Against Epilepsy – Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. **Epilepsia.** 30:4 (1989) 389-399.

COPPOLA, G. – Treatment of Partial Seizures in Childhood: An Overview. **CNS Drugs.** 18:3 (2004) 133-156.

COPPOLA, G. [*et al.*] – The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience. **Epilepsy Res.** 48:3 (2002) 221-227.

COSTA, J.C. – Surgical treatment of epilepsies in children. **J. Pediatr. (Rio J.)**, 78:Suppl 1 (2002) S28-S39.

CROM, W.R. – Effect of chirality on Pharmacokinetics and pharmacodynamics. **Am. J. Hosp. Pharm.** 49:9 Suppl. 1 (1992) S9-S14.

DADGAR, D.; BURNETT, P.E. – Issues in evaluation of bioanalytical method selectivity and drug stability. **J. Pharm. Biomed. Anal.** 14:1-2 (1995) 23-31.

DADGAR, D. [*et al.*] – Application issues in bioanalytical method validation, sample analysis and data reporting. **J. Pharm. Biomed. Anal.** 13:2 (1995) 89-97.

- D'AMBROSIO, R. – The role of glial membrane ion channels in seizures and epileptogenesis. **Pharmacol. Ther.** 103:2 (2004) 95-108.
- DECKERS, C.L.P. [*et al.*] – Selection Criteria for the Clinical Use of the Newer Antiepileptic Drugs. **CNS Drugs.** 17:6 (2003) 405-421.
- DEGEN, P.H. [*et al.*] – The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. **Biopharm. Drug Dispos.** 15:6 (1994) 519-526.
- DELORENZO, R.J.; SUN, D.A.; DESHPANDE, L.S. – Cellular mechanisms underlying acquired epilepsy: The calcium hypothesis of the induction and maintenance of epilepsy. **Pharmacol. Ther.** 105:3 (2005) 229-266.
- DICKINSON, R.G. [*et al.*] – First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. **Eur. J. Clin. Pharmacol.** 37:1 (1989) 69-74.
- DOMÉNECH BERROZPE, J; LAUROBA VILADROSA, J. – Farmacocinética no compartimental. In DOMÉNECH BERROZPE, J; MARTÍNEZ LANAO, J; PLÁ DELFINA, J.M., ed. lit. – **Biofarmacia y Farmacocinética.** Madrid: Editorial Síntesis, 1997. Vol 1, Cap. 18, p.391-420.
- DUA, T. [*et al.*] – Epilepsy Care in the World: Results of an ILAE/IBE/WHO Global Campaign Against Epilepsy Survey. **Epilepsia.** 47:7 (2006) 1225-1231.
- DUNCAN, J.S. – The promise of new antiepileptic drugs. **Br. J. Clin. Pharmacol.** 53:2 (2002) 123-131.
- DUNCAN, J.S. [*et al.*] – Adult epilepsy. **Lancet.** 367:9516 (2006) 1087-1100.
- EADIE, M.J. – Formation of Active Metabolites of Anticonvulsant Drugs: A Review of Their Pharmacokinetic and Therapeutic Significance. **Clin. Pharmacokinet.** 21:1 (1991) 27-41.
- ELGER, C. [*et al.*] – Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures. **Epilepsia.** 48:3 (2007) 497-504.
- ELWES, R.D.C.; BINNIE, C.D. – Clinical Pharmacokinetics of Newer Antiepileptic Drugs: Lamotrigine, Vigabatrin, Gabapentin and Oxcarbazepine. **Clin. Pharmacokinet.** 30:6 (1996) 403-415.
- ELYAS, A.A.; GOLDBERG, V.D.; PATSALOS, P.N. – Simple and rapid micro-analytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. **J. Chromatogr.** 528:2 (1990) 473-479.
- ENGELBORGHES, S.; D'HOOGHE, R.; DE DEYN, P.P. – Pathophysiology of epilepsy. **Acta Neurol. Belg.** 100:4 (2000) 201-213.
- ENGEL, J.Jr. – A Proposed Diagnostic Scheme for People with Epileptic Seizures and with Epilepsy: Report of the ILAE Task Force on Classification and Terminology. **Epilepsia.** 42:6 (2001) 796-803.
- ENGEL, J.Jr. – ILAE classification of epilepsy syndromes. **Epilepsy Res.** 70:Suppl. 1 (2006a) S5-S10.



- ENGEL, J.Jr. – Report of the ILAE Classification Core Group. **Epilepsia**. 47:9 (2006b) 1558-1568.
- ENGEL, J.Jr.; PEDLEY, T.A. – Introduction: What is epilepsy? In ENGEL, J.; PEDLEY, T.A., ed. lit. – **Epilepsy: A Comprehensive Textbook**. Philadelphia: Lippincott-Raven Publishers, 1997. Chap. 1, p.1-7.
- ENGEL, J.Jr.; WILSON, C.; BRAGIN, A. – Advances in Understanding the Process of Epileptogenesis Based on Patient Material: What Can the Patient Tell Us? **Epilepsia**. 44:Suppl. 12 (2003) 60-71.
- ESTEVES, A. – Antiepilépticos. In GARRETT, J.; OSSWALD, W.; GUIMARÃES, S., coord. – **Terapêutica Medicamentosa e suas Bases Farmacológicas**. 3ª ed. Porto: Porto Editora, 1997. Vol. I, Cap. 19, p.250-262.
- EVERITT, A.D.; SANDER, J.W.A.S. – Classification of the Epilepsies: Time for Change? A Critical Review of the International Classification of the Epilepsies and Epileptic Syndromes (ICEES) and Its Usefulness in Clinical Practice and Epidemiological Studies of Epilepsy. **Eur. Neurol.** 42:1 (1999) 1-10.
- FALCÃO, A. [et al.] – Effect of Gender on the Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093), a New Voltage-gated Sodium Channel Blocker. **Biopharm. Drug Dispos.** 28:5 (2007) 249-256.
- FERRENDELLI, J.A. – Concerns with Antiepileptic Drug Initiation: Safety, Tolerability, and Efficacy. **Epilepsia**. 42:Suppl. 4 (2001) 28-30.
- FISHER, R.S. [et al.] – Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). **Epilepsia**. 46:4 (2005) 470-472.
- FLESCH, G. – Overview of the Clinical Pharmacokinetics of Oxcarbazepine. **Clin. Drug Investig.** 24:4 (2004) 185-203.
- FLESCH, G. [et al.] – Determination of the R(-) and S(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. **J. Chromatogr.** 581:1 (1992) 147-151.
- FONTES-RIBEIRO, C. [et al.] – Eslicarbazepine Acetate (BIA 2-093). Relative Bioavailability and Bioequivalence of 50 mg/mL Oral Suspension and 200mg and 800mg Tablet Formulations. **Drugs R D**. 6:5 (2005) 253-260.
- FRANCESCHI, L.; FURLANUT, M. – A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. **Pharmacol. Res.** 51:4 (2005) 297-302.
- FREEMAN, J. [et al.] – The ketogenic diet: From molecular mechanisms to clinical effects. **Epilepsy Res.** 68:2 (2006) 145-180.
- FRENCH, J.A. – The Role of New Antiepileptic Drugs. **Am. J. Manag. Care.** 7:Suppl. 7 (2001) S209-S214.

- FRENCH, J.A. – Refractory Epilepsy: Clinical Overview. **Epilepsia**. 48:Suppl. 1 (2007) 3-7.
- FUKUYAMA, Y.; OSAWA, M. – To the epilepsy research 2006 supplement: Epileptic syndromes in infants and early childhood Evidence-based taxonomy and its implications in the ILAE classifications. **Epilepsy Res.** 70:Suppl. 1 (2006) S1-S3.
- GARERI, P. [*et al.*] – Treatment of Epilepsy in the Elderly. **Prog. Neurobiol.** 58:5 (1999) 389-407.
- GATTI, G. [*et al.*] – The New Antiepileptic Drugs: Pharmacological and Clinical Aspects. **Curr. Pharm. Des.** 6:8 (2000) 839-860.
- GIDAL, B.E.; GARNETT, W.R. – Epilepsy. In DIPIRO, J.T.; TALBERT, R.L.; YEE, G.C.; MATZKE, G.R.; WELLS, B.G.; POSEY, L.M., ed. lit. – **Pharmacotherapy. A Pathophysiologic Approach**. 6<sup>th</sup> ed. New York: McGraw-Hill, 2005. Chap. 54, p.1023-1048.
- GIL-NAGEL, A. – Review of New Antiepileptic Drugs as Initial Therapy. **Epilepsia**. 44:Suppl. 4 (2003) 3-10.
- GLAUSER, T.A. – Oxcarbazepine in the Treatment of Epilepsy. **Pharmacotherapy**. 21:8 (2001) 904-919.
- GLAUSER, T. [*et al.*] – ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. **Epilepsia**. 47:7 (2006) 1094-1120.
- GONZÁLEZ-ESQUIVEL, D.F. [*et al.*] – Plasma Level Monitoring of Oxcarbazepine in Epileptic Patients. **Arch. Med. Res.** 31:2 (2000) 202-205.
- GREEN, J.M. – A Practical Guide to Analytical Method Validation. **Anal. Chem.** 68 (1996) 305A-309A.
- GREINER, C.; HAEN, E. – Development of a simple column-switching high-performance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine and 10-monohydroxycarbazepine (MHD). **J. Chromatogr. B.** 854:1-2 (2007) 338-344.
- GROSS, M.; GOYAL, M. – Central Therapeutic Effects of Peripheral Vagus Nerve Stimulation. **Am. J. Electroneurodiagnostic Technol.** 47:1 (2007) 47-52.
- GROSS, R.A. – A brief history of epilepsy and its therapy in the Western Hemisphere. **Epilepsy Res.** 12:2 (1992) [abstract].
- GUBERMAN, A. – Vagus nerve stimulation in the treatment of epilepsy. **CMAJ.** 171:10 (2004) 1165-1166.
- GUIDANCE FOR INDUSTRY. – Bioanalytical Method Validation. U.S. Department of Health and Human Services, FDA, CDER, CVM, May 2001.
- GULATI, V. – Differential Properties of Enantiomers of Commercially Available Racemates. **J. Indian Med. Assoc.** 105:4 (2007) 173-176.

- GURJAR, M.K. – The Future Lies in Chiral Purity: A Perspective. **J. Indian Med. Assoc.** 105:4 (2007) 177-178.
- HAINZL, D.; PARADA, A.; SOARES-DA-SILVA, P. – Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. **Epilepsy Res.** 44:2-3 (2001) 197-206.
- HALLBOOK, T.; LUNDGREN, J.; ROSÉN, I. – Ketogenic Diet Improves Sleep Quality in Children with Therapy-resistant Epilepsy. **Epilepsia.** 48:1 (2007) 59-65.
- HAN, S.M. – Direct Enantiomeric Separations by High Performance Liquid Chromatography using Cyclodextrins. **Biomed. Chromatogr.** 11:5 (1997) 259-271.
- HARTMANN, C. [*et al.*] – Validation of bioanalytical chromatographic methods. **J. Pharm. Biomed. Anal.** 17:2 (1998) 193-218.
- HELLEBREKERS, L.J.; BOOIJ, L.H.D.J.; FLECKNELL, P.A. – Anaesthesia, analgesia and euthanasia. In VAN ZUPTHEN, L.F.M.; BAUMANS, V.; BEYNEN, A.C., ed. Lit. – **Principles of Laboratory Animal Science.** 2<sup>a</sup> ed. Amsterdam: Elsevier, 2003. Chap. 15, p.277-311.
- HENDERSON, C.B. [*et al.*] – Efficacy of the Ketogenic Diet as a Treatment Option for Epilepsy: Meta-analysis. **J. Child. Neurol.** 21:3 (2006) 193-198.
- HERMAN, S.T. – Clinical trials for prevention of epileptogenesis. **Epilepsy Res.** 68:1 (2006) 35-38.
- HIDAKA, M. [*et al.*] – Effects of Pomegranate Juice on Human Cytochrome P450 3A (CYP3A) and Carbamazepine Pharmacokinetics in Rats. **Drug Metab. Dispos.** 33:5 (2005) 644-648.
- HOOPER, J.W. – Bioanalytical Validation - A North American View. In BLUME, H.H.; MIDHA, K.K., ed. lit. – **Bioavailability, Bioequivalence and Pharmacokinetic Studies.** Stuttgart: Medpharm Scientific Publishers, 1995. p.347-355.
- HOOPER, W.D. [*et al.*] – Oxcarbazepine: Preliminary Clinical and Pharmacokinetic Studies on a New Anticonvulsant. **Clin. Exp. Neurol.** 24 (1987) 105-112.
- HUBERT, P. [*et al.*] – The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory. **Anal. Chim. Acta.** 391:2 (1999) 135-148.
- HUTT, A.J. – Chirality and Pharmacokinetics: an Area of Neglected Dimensionality? **Drug Metabol. Drug Interact.** 22:2-3 (2007) 79-112.
- HUTT, A.J.; TAN, S.C. – Drug Chirality and its Clinical Significance. **Drugs.** 52:Suppl. 5 (1996) 1-12.
- IORIO, M.L. [*et al.*] – Use and safety profile of antiepileptic drugs in Italy. **Eur. J. Clin. Pharmacol.** 63:4 (2007) 409-415.

ISLAM, M.R.; MAHDI, J.G.; BOWEN, I.D. – Pharmacological Importance of Stereochemical Resolution of Enantiomeric Drugs. **Drug Saf.** 17:3 (1997) 149-165.

JANCHAWEE, B. [*et al.*] – A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. **Biomed. Chromatogr.** 21:2 (2007) 176-183.

JARRAR, R.G.; BUCHHALTER, J.R. – Therapeutics in Pediatric Epilepsy, Part 1: The New Antiepileptic Drugs and the Ketogenic Diet. **Mayo Clin. Proc.** 78:3 (2003) 359-370.

JOHANNESSEN, S.I.; BEN-MENACHEM, E. – Management of Focal-Onset Seizures. An Update on Drug Treatment. **Drugs.** 66:13 (2006) 1701-1725.

JOHANNESSEN, S.I.; TOMSON, T. – Pharmacokinetic Variability of Newer Antiepileptic Drugs. When is Monitoring Needed? **Clin. Pharmacokinet.** 45:11 (2006) 1061-1075.

JUNG, H. [*et al.*] – The Distribution of 10-Hydroxy Carbamazepine in Blood Compartments. **Biopharm. Drug Dispos.** 18:1 (1997) 17-23.

KALIS, M.M.; HUFF, N.A. – Oxcarbazepine, an Antiepileptic Agent. **Clin. Ther.** 23:5 (2001) 680-700.

KARNES, H.T.; SHIU, G.; SHAH, V.P. – Validation of Bioanalytical Methods. **Pharm. Res.** 8:4 (1991) 421-426.

KEMENY, A.A. – Surgery for epilepsy. **Seizure.** 10:6 (2001) 461-465.

KETTER, T.A. [*et al.*] – Metabolism and Excretion of Mood Stabilizers and New Anticonvulsants. **Cell. Mol. Neurobiol.** 19:4 (1999) 511-532.

KHURANA, D.S. [*et al.*] – Vagus nerve stimulation in children with refractory epilepsy: unusual complications and relationship to sleep-disordered breathing. **Childs Nerv. Syst.** 23:11 (2007) 1309-1312.

KIM, K.J. [*et al.*] – Application of semiological seizure classification to epileptic seizures in children. **Seizure.** 11:5 (2002) 281-284.

KIM, Y.D. [*et al.*] – Antiepileptic Drug Withdrawal after Successful Surgery for Intractable Temporal Lobe Epilepsy. **Epilepsia.** 46:2 (2005) 251-257.

KING-STEPHENS, D. – The Treatment of Epilepsy in the Elderly. **CNS Drugs.** 12:1 (1999) 21-33.

KLITGAARD, H. – Antiepileptic drug discovery: lessons from the past and future challenges. **Acta Neurol. Scand.** 112:Suppl. 181 (2005) 68-72.

KLITGAARD, H. [*et al.*] – Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. **Eur. J. Pharmacol.** 353:2-3 (1998) 191-206.

- KLITGAARD, H.; PITKANEN, A. – Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. **Epileptic Disord.** 5:Suppl 1 (2003) S9-S16.
- KOSSOFF, E.H. – More fat and fewer seizures: dietary therapies for epilepsy. **Lancet Neurol.** 3:7 (2004) 415-420.
- KOSSOFF, E.H.; McGrogan, J.R. – Worldwide Use of the Ketogenic Diet. **Epilepsia.** 46:2 (2005) 280-289.
- KOSSOFF, E.H. [et al.] – Combined Ketogenic Diet and Vagus Nerve Stimulation: Rational Polytherapy? **Epilepsia.** 48:1 (2007) 77-81.
- KOTHARE, S.V. [et al.] – Oxcarbazepine Monotherapy in Children and Adolescents: A Single-Center Clinical Experience. **Pediatr. Neurol.** (2006) 35:4 (2006) 235-239.
- KRALL, R.L. [et al.] – Antiepileptic Drug Development: I. History and a Program for Progress. **Epilepsia.** 19:4 (1978) 393-408.
- KUBOVÁ, H.; MARES, P. – Anticonvulsant Action of Oxcarbazepine, Hydroxycarbamazepine, and Carbamazepine Against Metrazol-Induced Motor Seizures in Developing Rats. **Epilepsia.** 34:1 (1993) 188-192.
- KWAN, P.; BRODIE, M.J. – Combination Therapy in Epilepsy. When and What to Use. **Drugs.** 66:14 (2006) 1817-1829.
- LANCKMANS, K. [et al.] – Use of microbore LC-MS/MS for the quantification of oxcarbazepine and its active metabolite in rat brain microdialysis samples. **J. Chromatogr. B.** 831:1-2 (2006) 205-212.
- LANDMARK, C.J. – Antiepileptic Drugs in Non-Epilepsy Disorders. Relations between Mechanisms of Action and Clinical Efficacy. **CNS Drugs.** 22:1 (2008) 27-47.
- LEPPIK, E. – Treatment of Epilepsy in 3 Specialized Populations. **Am. J. Manag. Care.** 7:Suppl. 7 (2001) S221-S226.
- LEVERT, H.; ODOU, P.; ROBERT, H. – Simultaneous determination of four antiepileptic drugs in serum by high-performance liquid chromatography. **Biomed. Chromatogr.** 16:1 (2002) 19-24.
- LEVY, R.H.; BODDY, A.V. – Stereoselectivity in Pharmacokinetics: A General Theory. **Pharm. Res.** 8:5 (1991) 551-556.
- LONGRIGG, J. – Epilepsy in ancient Greek medicine – the vital step. **Seizure.** 9:1 (2000) 12-21.
- LOSCHER, W.; SCHMIDT, D. – New horizons in the development of antiepileptic drugs. **Epilepsy Res.** 50:1-2 (2002) 3-16.
- LOSCHER, W.; SCHMIDT, D. – New horizons in the development of antiepileptic drugs: Innovative strategies. **Epilepsy Res.** 69:3 (2006) 183-272.

LOWENSTEIN, D.H. – Seizures and Epilepsy. In KASPER, D.L.; FAUCI, A.S.; LONGO, D.L.; BRAUNWALD, E.; HAUSER, S.L.; JAMESON, J.L., ed. lit. – **Harrison's Principles of Internal Medicine**. 16<sup>th</sup> ed. New York: McGraw-Hill, 2004. Chap. 348, p.2357-2372.

LU, H. – Stereoselectivity in drug metabolism. **Expert Opin. Drug Metab. Toxicol.** 3:2 (2007) 149-158.

MAGGS, J.L. [*et al.*] – Characterization of the Metabolites of Carbamazepine in Patient Urine by Liquid Chromatography/Mass Spectrometry. **Drug Metab. Dispos.** 25:3 (1997) 275-280.

MAIA, J. [*et al.*] – Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093). **Drugs R D.** 6:4 (2005) 1-6.

MAIA, J. [*et al.*] – Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093) using a Chiral Method. **Epilepsia.** 47:Suppl. 6 (2006) 147 [Abstract].

MAIA, J. [*et al.*] – Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. **Int. J. Clin. Pharmacol. Ther.** 46:3 (2008) 119-130.

MANDRIOLI, R. [*et al.*] – Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solid-phase extraction. **J. Chromatogr. B.** 783:1 (2003) 253-263.

MARTINEZ, W. [*et al.*] – Efficacy, safety, and tolerability of oxcarbazepine monotherapy. **Epilepsy Behav.** 9:3 (2006) 448-456.

MARZO, A. – Incoming guidelines on chirality. A challenge for pharmacokinetics in drug development. **Arzneimittelforschung.** 44:6 (1994) 791-793.

MATAR, K.M. [*et al.*] – Effect of valproic acid on the pharmacokinetic profile of oxcarbazepine in the rat. **Pharm. Acta Helv.** 73:5 (1999) 247-250.

MAURER, H.H. [*et al.*] – Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry. **J. Mass Spectrom.** 37:7 (2002) 687-692.

MAY, T.W.; KORN-MERKER, E.; RAMBECK, B. – Clinical Pharmacokinetics of Oxcarbazepine. **Clin. Pharmacokinet.** 42:12 (2003) 1023-1042.

MAZZA, M. [*et al.*] – Oxcarbazepine improves mood in patients with epilepsy. **Epilepsy Behav.** 10:3 (2007) 397-401.

MAZZUCHELLI, I. [*et al.*] – Changes in the Disposition of Oxcarbazepine and Its Metabolites during Pregnancy and the Puerperium. **Epilepsia.** 47:3 (2006) 504-509.

MAZZUCHELLI, I. [*et al.*] – A Novel Enantioselective Microassay for the High-Performance Liquid Chromatography Determination of Oxcarbazepine and Its Active Metabolite Monohydroxycarbazepine in Human Plasma. **Ther. Drug Monit.** 29:3 (2007) 319-324.

- MCAULEY, J.W.; ANDERSON, G.D. – Treatment of Epilepsy in Women of Reproductive Age: Pharmacokinetic Considerations. **Clin. Pharmacokinet.** 4:8 (2002) 559-579.
- MCLEAN, M.J. [et al.] – Oxcarbazepine: Mechanism of Action. **Epilepsia.** 35:Suppl. 3 (1994) S5-S9.
- MCMANARA, J.O. – Pharmacotherapy of the Epilepsies. In BRUNTON, L.L.; LAZO, J.S.; PARKER, K.L., ed. lit. – **Goodman and Gilman's The Pharmacological Basis of Therapeutics.** 11<sup>th</sup> ed. New York: McGraw-Hill, 2006. Chap. 19, p.501-525.
- MELDRUM, B.S.; ROGAWSKI, M.A. – Molecular Targets for Antiepileptic Drug Development. **Neurotherapeutics.** 4:1 (2007) 18-61.
- MENGE, G.; DUBOIS, J.P. – Determination of oxcarbazepine in human plasma by high-performance liquid chromatography. **J. Chromatogr.** 275:1 (1983) 189-194.
- MENGE, G.P.; DUBOIS, J.P.; BAUER, G. – Simultaneous determination of carbamazepine, oxcarbazepine and their main metabolites in plasma by liquid chromatography. **J. Chromatogr.** 414:2 (1987) 477-483.
- MESDJIAN, E. [et al.] – Metabolism of Carbamazepine by CYP3A6: A Model for In Vitro Drug Interactions Studies. **Life Sci.** 64:10 (1999) 827-835.
- MISL'ANOVÁ, C.; HUTTA, M. – Role of biological matrices during the analysis of chiral drugs by liquid chromatography. **J. Chromatogr. B.** 797:1-2 (2003) 91-109.
- MOSEWICH, R.K.; SO, E.L. – A Clinical Approach to the Classification of Seizures and epileptic Syndromes. **Mayo Clin. Proc.** 71:4 (1996) 405-414.
- MYLLYNEN, P. [et al.] – Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. **Hum. Exp. Toxicol.** 17:12 (1998) 668-676.
- MYLLYNEN, P. [et al.] – Transplacental Passage of Oxcarbazepine and Its Metabolites In Vivo. **Epilepsia.** 42:11 (2001) 1482-1485.
- NAGARAJAN, L. [et al.] – VNS therapy in clinical practice in children with refractory epilepsy. **Acta Neurol. Scand.** 105:1 (2002) 13-17.
- NATSCH, S. [et al.] – Newer Anticonvulsant Drugs: Role of Pharmacology, Drug Interactions and Adverse Reactions in Drug Choice. **Drug Saf.** 17:4 (1997) 228-240.
- NEELS, H.M. [et al.] – Therapeutic drug monitoring of old and newer antiepileptic drugs. **Clin. Chem. Lab. Med.** 42:11 (2004) 1228-1255.
- NOIRFALISE, A.; COLLINGE, A. – Quantitative determination of oxcarbazepine. **J. Chromatogr.** 274 (1983) 417-420.
- NUNES, T. [et al.] – Pharmacokinetics of Eslicarbazepine Acetate in Children and Adolescents with Epilepsy. **Epilepsia.** 48:Suppl. 7 (2007) 136[Abstract].

- OHNISHI, N. [*et al.*] – Studies on Interactions between Traditional Herbal and Western Medicines. V. Effects of Sho-saiko-to (Xiao-Cai-hu-Tang) on the Pharmacokinetics of Carbamazepine in Rats. **Biol. Pharm. Bull.** 25:11 (2002) 1461-1466.
- OIJEN, M.V. [*et al.*] – Resective epilepsy surgery in childhood: The Dutch experience 1992-2002. **Eur. J. Paediatr. Neurol.** 10:3 (2006) 114-123.
- PARADA, A.; SOARES-DA-SILVA, P. – The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. **Neurochem. Int.** 40:5 (2002) 435-440.
- PATIL, P.A.; KOTHEKAR, M.A. – Development of Safer Molecules Through Chirality. **Indian J. Med. Sci.** 60:10 (2006) 427-437.
- PEARCE, J.M.S. – Bromide, the first effective antiepileptic agent. **J. Neurol. Neurosurg. Psychiatry.** 72:3 (2002) 412.
- PERUCCA, E. – Clinical pharmacology and therapeutic use of the new antiepileptic drugs. **Fundam. Clin. Pharmacol.** 15:6 (2001) 405-417.
- PERUCCA, E. – Marketed New Antiepileptic Drugs: Are They Better Than Old-Generation Agents? **Ther. Drug Monit.** 24:1 (2002a) 74-80.
- PERUCCA, E. – Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. **CNS Drugs.** 16:10 (2002b) 695-714.
- PERUCCA, E. – An Introduction to Antiepileptic Drugs. **Epilepsia.** 46:Suppl. 4 (2005) 31-37.
- PERUCCA, E. – Clinically relevant drug interactions with antiepileptic drugs. **Br. J. Clin. Pharmacol.** 61:3 (2006a) 246-255.
- PERUCCA, E. – Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age. **Clin. Pharmacokinet.** 45:4 (2006b) 351-363.
- PERUCCA, E.; FRENCH, J.; BIALER, M. – Development of new antiepileptic drugs: challenges, incentives, and recent advances. **Lancet Neurol.** 6:9 (2007) 793-804.
- PETERS, F.T.; MAURER, H.H. – Bioanalytical method validation and its implications for forensic and clinical toxicology - A review. **Accred. Qual. Assur.** 7:11 (2002) 441-449.
- PICHINI, S. [*et al.*] – Stereoselective Bioanalysis of Oxcarbazepine and the Enantiomers of its Metabolites by High-Performance Liquid Chromatography. **J. Liq. Chromatogr.** 18:8 (1995) 1533-1541.
- PIENIMAKI, P. [*et al.*] – Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography. **J. Chromatogr. B.** 673:1 (1995) 97-105.



- POSTMA, T. [*et al.*] – Lamotrigine Treatment During Amygdala-Kindled Seizure Development Fails to Inhibit Seizures and Diminishes Subsequent Anticonvulsant Efficacy. **Epilepsia**. 41:12 (2000) 1514-1521.
- POTSCHKA, H.; PEKCEC, A.; SOARES-DA-SILVA, P. – Inhibition of Kindling Progression by Eslicarbazepine Acetate and Licarbazepine. **Epilepsia**. 48:Suppl. 7 (2007) 60 [Abstract].
- PYONNÖNEN, S. – Pharmacokinetics of Carbamazepine in Man: A Review. **Ther. Drug Monit.** 1:3 (1979) 409-431.
- REITH, D.M. [*et al.*] – The Effect of Body Size on the Metabolic Clearance of Carbamazepine. **Biopharm. Drug Dispos.** 21:3 (2000) 103-111.
- RENTSCH, K.M. – The importance of stereoselective determination of drugs in clinical laboratory. **J. Biochem. Biophys. Methods** 54:1-3 (2002) 1-9.
- REY, E. [*et al.*] – Oxcarbazepine Pharmacokinetics and Tolerability in Children with Inadequately Controlled Epilepsy. **J. Clin. Pharmacol.** 44:11 (2004) 1290-1300.
- ROFFEY, S.J. [*et al.*] – The Disposition of Voriconazole in Mouse, Rat, Rabbit, Guinea Pig, Dog, and Human. **Drug Metab. Dispos.** 31:6 (2003) 731-741.
- ROGAWSKI, M.A. – Diverse mechanisms of antiepileptic drugs in the development pipeline. **Epilepsy Res.** 69:3 (2006) 273-294.
- ROUAN, M.C. [*et al.*] – Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography. **J. Chromatogr. B.** 658:1 (1994) 167-172.
- SACHDEO, R. [*et al.*] – Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy. **Epilepsy Behav.** 9:3 (2006) 457-463.
- SANDER, J.W. – The Use of Antiepileptic Drugs. Principles and Practice. **Epilepsia**. 45:Suppl. 6 (2004) 28-34.
- SASA, M. – A New Frontier in Epilepsy: Novel Antiepileptogenic Drugs. **J. Pharmacol. Sci.** 100:5 (2006) 487-494.
- SAVICA, R. [*et al.*] – Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. **Eur. J. Neurol.** 14:12 (2007) 1317-1321.
- SCHACHTER, S.C. – Oxcarbazepine: current status and clinical applications. **Expert Opin. Investig. Drugs.** 8:7 (1999) 1103-1112.
- SCHMIDT, D. – The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. **Epilepsy Res.** 50:1-2 (2002) 21-32.

SCHMIDT, D.; BAUMGARTNER, C.; LOSCHER, W. – Seizure Recurrence after Planned Discontinuation of Antiepileptic Drugs in Seizure-free Patients after Epilepsy Surgery: A Review of Current Clinical Experience. **Epilepsia**. 45:2 (2004) 179-186.

SCHMIDT, D.; ELGER, C.E. – What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? **Epilepsy Behav.** 5:5 (2004) 627-635.

SCHMUTZ, M. [et al.] – Oxcarbazepine: Preclinical Anticonvulsant Profile and Putative Mechanisms of Action. **Epilepsia**. 35:Suppl. 5 (1994) S47-S50.

SCHÜTZ, H. [et al.] – The metabolism of <sup>14</sup>C-oxcarbazepine in man. **Xenobiotica**. 16:8 (1986) 769-778.

SCHWABE, S.K. – Challenges in the Clinical Development of New Antiepileptic Drugs. **Ther. Drug Monit.** 24:1 (2002) 81-84.

SEGARRA, I.; MOVSHIN, D.A.; ZARIF, L. – Pharmacokinetics and Tissue Distribution after Intravenous Administration of a Single Dose of Amphotericin B Cochleates, a New Lipid-Based Delivery System. **J. Pharm. Sci.** 91:8 (2002) 1827-1837.

SEINO, M. – Classification criteria of epileptic seizures and syndromes. **Epilepsy Res.** 70:Suppl. 1 (2006) S27-S33.

SHAEFI, S.; HARKNESS, W. – Current Status of Surgery in the Management of Epilepsy. **Epilepsia**. 44:Suppl. 1 (2003) 43-47.

SHAH, V.P. [et al.] – Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies. **Pharm. Res.** 9:4 (1992) 588-592.

SHAH, V.P. [et al.] – Bioanalytical Method Validation - A Revisit with a Decade of Progress. **Pharm. Res.** 17:12 (2000) 1551-1557.

SHETH, R.D. – Intractable Pediatric epilepsy: Presurgical Evaluation. **Semin. Pediatr. Neurol.** 7:3 (2000) 158-165.

SHETH, R.D. [et al.] – Pediatric Epilepsy Surgery: Neuroimaging, Neuropsychology, and Anticonvulsants. **Semin. Pediatr. Neurol.** 7:3 (2000) 166-177.

SHETH, R.D.; STAFSTROM, C.E.; HSU, D. – Nonpharmacological Treatment Options for Epilepsy. **Semin. Pediatr. Neurol.** 12:2 (2005) 106-113.

SHORVON, S.D. – Octeto de la Epilepsia: Epidemiología, clasificación, evolución natural y genética de la epilepsia. **Lancet (Ed. Esp.)**. 17:6 (1990) 334-338.

SIERRA-PAREDES, G. [et al.] – Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. **Epilepsy Res.** 72:2-3 (2006) 140-146.

- SIERRA-PAREDES, G. [*et al.*] – Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. **Epilepsy Res.** 77:1 (2007) 36-43.
- SMITH, C.T. [*et al.*] – Multiple treatment comparisons in epilepsy monotherapy trials. **Trials.** 8:1 (2007) 34-43.
- SMITH, M; WILCOX, K.S.; WHITE, H.S. – Discovery of Antiepileptic Drugs. **Neurotherapeutics.** 4:1 (2007) 12-17.
- SRINIVAS, N.R.; BARBHAIYA, R.H.; MIDHA, K.K. – Enantiomeric Drug Development: Issues, Considerations, and Regulatory Requirements. **J. Pharm. Sci.** 90:9 (2001) 1205-1215.
- SOARES-DA-SILVA, P. [*et al.*] – Effect of Age and Gender on the Pharmacokinetics of Eslicarbazepine Acetate. **Epilepsia.** 46:Suppl. 8 (2005) 216[Abstract].
- SORIANO, T. [*et al.*] – Improved Solid-Phase Extraction Method for Systematic Toxicological Analysis in Biological Fluids. **J. Anal. Toxicol.** 25:2 (2001) 137-143.
- SOUPPART, C. [*et al.*] – Development of a high throughput 96-well plate sample preparation method for the determination of levetiracetam (oxcarbazepine) and its metabolites in human plasma. **J. Chromatogr. B.** 762:1 (2001) 9-15.
- SOUPPART, C. [*et al.*] – Pharmacokinetics of Licarbazepine in Healthy Volunteers: Single and Multiple Oral Doses and Effect of Food. **J. Clin. Pharmacol.** 45:5 (2008) 563-569.
- SPINA, E.; PISANI, F.; PERUCCA, E. – Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine . An Update. **Clin. Pharmacokinet.** 31:3 (1996) 198-214.
- STAFSTROM, C.E. – Dietary Approaches to Epilepsy Treatment: Old and New Options on the Menu. **Epilepsy Curr.** 4:6 (2004) 215-222.
- STEPHAN, H. [*et al.*] – Epileptogenesis and rational therapeutic strategies. **Acta Neurol. Scand.** 113:3 (2006) 139-155.
- STEPHAN, H.; FEUERSTEIN, T.J. – Novel anticonvulsant drugs. **Pharmacol. Ther.** 113:1 (2007) 165-183.
- STEPHAN, L.J.; BRODIE, M.J. – Seizure freedom with more than one antiepileptic drug. **Seizure.** 11:6 (2002) 349-351.
- STRATTON, S.C. [*et al.*] – Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. **Epilepsy Res.** 53:1-2 (2003) 95-106.
- SUTULA, T.P. – Epilepsy after the Decade of the Brain: Misunderstandings, challenges, and opportunities. **Epilepsy Behav.** 6:3 (2005) 296-302.

TARTARA, A. [*et al.*] – The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. **Br. J. Clin. Pharmacol.** 36:4 (1993) 366-368.

TECOMA, E.S.; IRAGUI, V.J. – Vagus nerve stimulation use and effect in epilepsy: What have we learned? **Epilepsy Behav.** 8:1 (2006) 127-136.

THOMSON, A.H.; BRODIE, M.J. – Pharmacokinetic Optimisation of Anticonvulsant Therapy. **Clin. Pharmacokinet.** 23:3 (1992) 216-230.

TOMSON, T. – Drug selection for the newly diagnosed patient: When is a new generation antiepileptic drug indicated? **J. Neurol.** 251:9 (2004) 1043-1049.

TOMSON, T. – Gender Aspects of Pharmacokinetics of New and Old AEDs: Pregnancy and Breast-Feeding. **Ther. Drug. Monit.** 27:6 (2005) 718-721.

VAN BELLE, K. [*et al.*] – Brain, Liver and Blood Distribution Kinetics of Carbamazepine and Its Metabolic Interaction with Clomipramine in Rats: A Quantitative Microdialysis Study. **J. Pharmacol. Exp. Ther.** 272:3 (1995) 1217-1222.

VAN DER KUY, P.H.; KOPPEJAN, E.H.; WIRTZ, J.J. – Rectal absorption of oxcarbazepine. **Pharm. World Sci.** 22:4 (2000) 165-166.

VANEY, C. – The mind and epilepsy: opinions and viewpoints over the course of time. **Schweiz Rundsch Med. Prax.** 78:29-30 (1989) [abstract].

VAN HEININGEN, P.N. [*et al.*] – The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. **Clin. Pharmacol. Ther.** 50:4 (1991) 410-419.

VAN ZUPTHEN, L.F.M. – Introduction. In VAN ZUPTHEN, L.F.M.; BAUMANS, V.; BEYNEN, A.C., ed. lit. – **Principles of Laboratory Animal Science**. 2<sup>nd</sup> ed. Amsterdam: Elsevier, 2003. Chap. 1, p.1-10.

VASCONCELOS-DUENAS, D. – Epilepsy: an incapacitating disease? Propitiatory topic for a free program for epileptics. **Gac. Med. Mex.** 137:1 (2001) 73-78.

VELPANDIAN, T. [*et al.*] – Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. **J. Chromatogr. B.** 804:2 (2004) 431-434.

VESSMAN, J. [*et al.*] – Selectivity in Analytical Chemistry. **Pure Appl. Chem.** 73:8 (2001) 1381-1386.

VOLOSOV, A. [*et al.*] – Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. **Clin. Pharmacol. Ther.** 66:6 (1999) 547-553.

- VOLOSOV, A. [et al.] – Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbamazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. **J. Chromatogr. B.** 738:2 (2000) 419-425.
- VOLOSOV, A.; YAGEN, B.; BIALER, M. – Comparative Stereoselective Pharmacokinetic Analysis of 10-Hydroxycarbamazepine After Oral Administration of its Individual Enantiomers and the Racemic Mixture to Dogs. **Epilepsia.** 41:9 (2000) 1107-1111.
- WAMIL, A.W. [et al.] – Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. **Eur. J. Pharmacol.** 271:2-3 (1994) 301-308.
- WANG, X.; CHING, C.B. – Liquid Chromatographic Retention Behavior and Enantiomeric Separation of Three Chiral Center  $\beta$ -Blocker Drug (Nadolol) Using Heptakis (6-Azido-6deoxy-2, 3-di-O-phenylcarbamolyted)  $\beta$ -Cyclodextrin Bonded Chiral Stationary Phase. **Chirality.** 14:10 (2002) 798-805.
- WELLINGTON, K.; GOA, K.L. – Oxcarbazepine: An Update of its Efficacy in the Management of Epilepsy. **CNS Drugs.** 15:2 (2001) 137-163.
- WHITE, H.S. – Preclinical Development of Antiepileptic Drugs: Past, Present, and Future Directions. **Epilepsia.** 44:Suppl. 7 (2003) 2-8.
- WIEBE, S. [et al.] – A randomized, controlled trial of surgery for temporal-lobe epilepsy. **N. Engl. J. Med.** 345:5 (2001) 311-318.
- WIELING, J. [et al.] – Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma. **J. Chromatogr. A.** 730:1-2 (1996) 381-394.
- WOLF, P. – International Classification of the Epilepsies. In ENGEL, J.; PEDLEY, T.A., ed. lit. – **Epilepsy: A Comprehensive Textbook.** Philadelphia: Lippincott-Raven Publishers, 1997. Chap. 68, p.773-777.
- WOLF, P. – Basic principles of the ILAE syndrome classification. **Epilepsy Res.** 70:Suppl. 1 (2006) S20-S26.
- WSÓL, V.; SKÁLOVÁ, L.; SZOTÁKOVÁ, B. – Chiral Inversion of Drugs: Coincidence or Principle? **Curr. Drug Metab.** 5:6 (2004) 517-533.
- YAMAOKA, K.; NAKAGAWA, T.; UNO, T. – Statistical Moments in Pharmacokinetics. **J. Pharmacokinet. Biopharm.** 6:6 (1978) 547-558.
- YAMASHITA, F.; HASHIDA, M. – *In Silico* Approaches for Predicting ADME Properties of Drugs. **Drug Metab. Pharmacokinet.** 19:5 (2004) 327-338.
- ZHU, Y. [et al.] – Liquid chromatography/tandem mass spectrometry for the determination of carbamazepine and its main metabolite in rat plasma utilizing an automated blood sampling system. **J. Pharm. Biomed. Anal.** 38:1 (2005) 119-125.